A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

被引：11

作者：

Zhou, Caicun ^{[1
]}

Hu, Yanping

Arkania, Ekaterine ^{[3
]}

Kilickap, Saadettin ^{[4
,21
]}

Ying, Kejing ^{[5
]}

Xu, Fei ^{[6
]}

Wu, Lin ^{[7
]}

Wang, Xiang ^{[8
]}

Viguro, Maksym ^{[20
]}

Makharadze, Tamta ^{[3
]}

Sun, Hongmei ^{[9
]}

Luo, Feng ^{[10
]}

Shi, Jianhua ^{[11
]}

Zang, Aimin ^{[12
]}

Pan, Yueyin ^{[13
]}

Chen, Zhendong ^{[14
]}

Jia, Zhongyao ^{[15
]}

Kuchava, Vladimer ^{[16
]}

Lu, Ping ^{[17
]}

Zhang, Ling ^{[18
]}

Cheng, Ying ^{[19
]}

Kang, Wenying ^{[20
]}

Wang, Qingyu ^{[19
]}

Yu, Haoyu ^{[20
]}

Li, Jing ^{[1
,20
]}

Zhu, Jun ^{[20
]}

机构：

[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China

[2] Hubei Canc Hosp, Dept Med Oncol, Wuhan 430000, Peoples R China

[3] LTD Israeli Georgian Med Res Clin Helsicore, GE-0112 Tbilisi, Georgia

[4] Hacettepe Univ, Fac Med, Dept Med Oncol, TR-06230 Ankara, Turkiye

[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pneumol, Hangzhou 310016, Peoples R China

[6] Nanchang Univ, Affiliated Hosp 1, Dept Pneumol, Nanchang 330006, Peoples R China

[7] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha 410013, Peoples R China

[8] Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou 221009, Peoples R China

[9] Jiamusi Tumor Hosp, Dept Med Oncol, Jiamusi 154007, Peoples R China

[10] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu 610041, Peoples R China

[11] Linyi Canc Hosp, Dept Med Oncol, Linyi 276000, Peoples R China

[12] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China

[13] Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Med Oncol, Hefei 230001, Peoples R China

[14] Anhui Med Univ, Affiliated Hosp 2, Dept Med Oncol, Hefei 230601, Peoples R China

[15] Linyi Peoples Hosp, Dept Oncol, Linyi 276002, Peoples R China

[16] LTD Inst Clin Oncol, GE-0159 Tbilisi, Georgia

[17] Xinxiang Med Univ, Affiliated Hosp 1, Dept Oncol, Xinxiang 453100, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Peoples R China

[19] Jilin Canc Hosp, Dept Oncol, Changchun 130012, Peoples R China

[20] Shanghai Henlius Biotech Inc, Shanghai 200233, Peoples R China

[21] Istinye Univ, Fac Med, Dept Med Oncol, TR-34010 Istanbul, Turkiye

来源：

CANCER CELL | 2024年 / 42卷 / 02期

关键词：

NAB-PACLITAXEL; GEMCITABINE; CARBOPLATIN; PLACEBO; TRIAL;

D O I：

10.1016/j.ccell.2023.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Combining immunotherapy with chemotherapy can provide improved survival in advanced squamous nonsmall -cell lung cancer (NSCLC) patients without targetable gene alterations. 537 previously untreated patients with stage IIIB/IIIC or IV squamous NSCLC without targetable gene alterations were enrolled and randomized (2:1) to receive serplulimab 4.5 mg/kg or placebo, both in combination with nab-paclitaxel and carboplatin, intravenously in 3 -week cycles. The primary endpoint of progression -free survival (PFS) was met at the first interim analysis. At the second interim analysis, PFS benefit was maintained in serplulimab-chemotherapy group (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.42-0.67). At the final analysis, serplulimab-chemotherapy significantly improved median OS compared to placebo -chemotherapy (HR 0.73, 95% CI 0.58-0.93; p = 0.010). Grade R3 serplulimab or placebo -related adverse events occurred in 126 (35.2%) and 58 (32.4%) patients, respectively. Our results demonstrate that adding serplulimab to chemotherapy significantly improves survival in advanced squamous NSCLC patients, with manageable safety.

引用

页码：198 / 208.e3

页数：15

共 50 条

[41] A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer
Jiang, Haiping
Zhang, Xiaochen
Chen, Jing
Zhang, Ling
Xiong, Jianping
Zhong, Lin
Yu, Feng
Qian, Jiong
Yu, Lanfang
Wang, Xiaoting
Shi, Genming
Deng, Jing
Xu, Nong
JOURNAL OF THORACIC DISEASE, 2014, 6 (02) : 79 - 85
[42] A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
Ahn, Jin Seok
Lee, Ki Hyeong
Sun, Jong-Mu
Park, Keunchil
Kang, Eun-Suk
Cho, Eun Kyung
Lee, Dae Ho
Kim, Sang-We
Lee, Gyeong-Won
Kang, Jin-Hyoung
Lee, Jong-Seok
Lee, Jae-Won
Ahn, Myung-Ju
LUNG CANCER, 2013, 82 (03) : 455 - 460
[43] First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions
Jiang, Panpan
Geng, Luying
Mao, Ziyang
Wang, Qinyang
Wang, Wenjuan
Jiao, Min
Yao, Yu
Chen, Nanzheng
Zhang, Jia
Nan, Kejun
Shen, Yuan
Guo, Hui
Jiang, Lili
IMMUNOTHERAPY, 2022, 14 (06) : 445 - 457
[44] Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer
Hirsch, Fred R.
Govindan, Ramaswamy
Zvirbule, Zanete
Braiteh, Fadi
Rittmeyer, Achim
Belda-Iniesta, Cristobal
Isla, Dolores
Cosgriff, Thomas
Boyer, Michelle
Ueda, Masamichi
Phan, See
Gandara, David R.
CLINICAL LUNG CANCER, 2017, 18 (01) : 43 - 49
[45] A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
Villaruz, Liza C.
Cobo, Manuel
Syrigos, Konstantinos
Mavroudis, Dimitrios
Zhang, Wei
Kim, Jong Seok
Socinski, Mark A.
LUNG CANCER, 2019, 136 : 52 - 56
[46] Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in Advanced Non-small-Cell Lung Cancer in the United States
Lang, Kathleen
Marciniak, Martin D.
Faries, Douglas
Stokes, Michael
Buesching, Don
Earle, Craig
Treat, Joseph
Babineaux, Steve
Morissette, Nathalie
Thompson, David
VALUE IN HEALTH, 2009, 12 (04) : 481 - 488
[47] Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer
Twelves, C.
Chmielowska, E.
Havel, L.
Popat, S.
Swieboda-Sadlej, A.
Sawrycki, P.
Bycott, P.
Ingrosso, A.
Kim, S.
Williams, J. A.
Chen, C.
Olszanski, A. J.
de Besi, P.
Schiller, J. H.
ANNALS OF ONCOLOGY, 2014, 25 (01) : 132 - 138
[48] Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
Adderley, Helen
Ackermann, Christoph Jakob
Califano, Raffaele
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
[49] First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype
Tiseo, Marcello
Bartolotti, Marco
Gelsomino, Francesco
Ardizzoni, Andrea
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 425 - 435
[50] Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer:: a lung cancer Galician group phase II study
Casal, Joaquin
Amenedo, Margarita
Mel, Jose Ramon
Anton, Luis Miguel
Rodriguez-Lopez, Ruben
Lopez-Lopez, Rafael
Gonzalez-Ageitos, Ana
Castellanos, Javier
Constenla, Manuel
Tisaire, Jose L.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 725 - 732

← 1 2 3 4 5 →